Sigumir vs TB-500
Comparison of Sigumir (Low evidence) and TB-500 (Moderate evidence).
Last updated: February 12, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Sigumir
Dossier overview
TB-500
Dossier overview
Overview
Sigumir and TB-500 are both studied in the peptide research space.
Sigumir: A cytamin-class peptide supplement derived from cartilage tissue, part of the Russian bioregulator framework.
TB-500: A synthetic fragment of thymosin beta-4 marketed for tissue repair.
Evidence Comparison
| Aspect | Sigumir | TB-500 |
|---|---|---|
| Evidence Level | Low | Moderate |
| Human Studies | 1 | 8 |
| Preclinical Studies | 5 | 20 |
| Total Sources | 7 | 34 |
Key Differences
| Aspect | Sigumir | TB-500 |
|---|---|---|
| Category | Repair & Recovery | Repair & Recovery |
| Evidence Strength | Low | Moderate |
| Total Sources | 7 | 34 |
| Human Studies | 1 | 8 |
Summary
- Sigumir: Low evidence with 7 total sources (1 human)
- TB-500: Moderate evidence with 34 total sources (8 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.